Physician profile
Michael S Gersch
NPI 1326068867
$10,058.86
in general payments reported to CMS, 2019-2025
25 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $476 · 2021: $1,386 · 2022: $1,095 · 2023: $2,599 · 2024: $3,092 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,487 · Travel and Lodging: $2,079 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,486.67 |
| Travel and Lodging | $2,078.80 |
| Education | $191.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,281.93 | 2021-2024 | Ellipsys Vascular Access System, Chameleon |
| Mozarc Medical US LLC | $1,497.85 | 2024 | Argyle |
| Travere Therapeutics, INC. | $681.89 | 2019-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $465.94 | 2019-2024 | Farxiga |
| Amgen INC. | $375.71 | 2020-2025 | Krystexxa, Tavneos |
| Mallinckrodt Hospital Products INC. | $304.88 | 2020-2025 | Acthar |
| Ardelyx, INC. | $304.68 | 2024-2025 | Ibsrela |
| Horizon Therapeutics Plc | $258.21 | 2019-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $206.76 | 2020-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $176.98 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $175.02 | 2022-2025 | |
| Bard Peripheral Vascular, INC. | $164.48 | 2020-2021 | |
| Akebia Therapeutics INC | $157.48 | 2019-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $148.71 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $130.96 | 2019-2025 | Veltassa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $125.08 | 2020-2023 | Benlysta |
| Boston Scientific Corporation | $122.08 | 2019-2023 | Small Peripheral Cutting Balloon |
| Merit Medical Systems INC | $109.21 | 2025 | Wrapsody Stent Graft |
| Aurinia Pharma U.S., INC. | $87.21 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $82.45 | 2022-2025 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $63.31 | 2021-2023 | Gattex |
| Novo Nordisk INC | $41.89 | 2024-2025 | Wegovy, Ozempic |
| Becton, Dickinson and Company | $37.40 | 2025 | Conquest, Fluency Endovascular Stent Graft |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.87 | 2025 | Jardiance |
| Ethicon US, LLC | $28.88 | 2024 | Ethicon, Evarrest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gersch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.